SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

 Division of Infectious Diseases

[Return To Index page]
photo Minh-Hong Nguyen, MD

Professor of Medicine

Director, Transplant Infectious Diseases

Director, Antimicrobial Management Program

Email: nguyenh@dom.pitt.edu

Phone: 412-647-0996

Contact
Office: University of Pittsburgh, ID Division
3550 Fifth Avenue, Suite S872 Scaife Hall
Pittsburgh, PA 15261
 
Phone: 412-647-0996
Fax: 412-648-8455
E-mail: nguyenh@dom.pitt.edu
Education and Training
Education
B.S. - Chemistry and Physics, Elizabeth College, Elizabethtown, PA, 1984
M.D., Temple University School of Medicine, 1988
Training
Residency - Internal Medicine, University of Pittsburgh, School of Medicine, 1991
Fellowship - Infectious Diseases, University of Pittsburgh Health Center, 1995
Research Interest
Dr. Nguyen's multiple research interests are medical mycology research, including projects on the mechanisms and clinical impact of antifungal drug resistance, and molecular pathogenesis of invasive Candida infections. Since 2016, she extended her interest in Zygomycetes genetics and epidemiology. In addition, her research focuses on XDR bacterial and antimicrobial stewardship research, including projects on evolution and tolerance/resistance and pathogenic mechanisms of carbapenem-resistant Enterobacteriaceae (CRE) and other Gram negative bacteria; the development of novel antibiotic treatment strategies based upon bacterial genetics and pharmacokinetic-pharmacodynamic (PK-PD) principles; the clinical and economic impact of XDR infections and antimicrobial stewardship interventions; and clinical trials of new antimicrobials and diagnostic tests. Dr. Nguyen's Transplant Infectious Diseases (TID) research includes projects on the role of the microbiome in infections and outcomes among transplant recipients, the impact of rectal CRE carriage on transplant patients' outcome, and clinical studies and trials on a wide range of opportunistic fungal, bacterial, and viral infections.
Publications
Selected Publications:
Cheng, S, Clancy, CJ, Xu, W, Schneider, F, Hao, B, Mitchell, AP, Nguyen, MH. Profiling of Candida albicans gene expression during intra-abdominal candidiasis identifies biologic processes involved in pathogenesis. Journal of Infectious Diseases. 2013; 208(9): 1529-37.
Cheng, S, Clancy, CJ, Hartman, DJ, Hao, B, Nguyen, MH. Candida glabrata intra-abdominal candidiasis is characterized by persistence within the peritoneal cavity and abscesses. Infection and Immunity. 2014; 82(7): 3015-22.
Vergidis, P, Clancy, CJ, Shields, RK, Park, SY, Wildfeuer, BN, Simmons, RL, Nguyen, MH. Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment. PLoS One. 2016; 11(4): e0153247.
Eschenauer, GA, Kwak, EJ, Humar, A, Potoski, BA, Clarke, LG, Shields, RK, Abdel-Massih, R, Silveira, FP, Vergidis, P, Clancy, CJ, Nguyen, MH. Targeted versus universal antifungal prophylaxis among liver transplant recipients. American Journal of Transplantation. 2015; 15(1): 180-9.
Haidar, G, Alkroud, A, Cheng, S, Churilla, TM, Churilla, BM, Shields, RK, Doi, Y, Clancy, CJ, Nguyen, MH. Association between presence of aminoglycoside modifying enzymes and in vitro activity of gentamicin, tobramycin, amikacin and plazomicin against KPC and ESBL-producing Enterobacter spp. Antimicrobial Agents and Chemotherapy. 2015; AAC.00869-16.
Sponsored Research/Activities
Title: Chromosomal and Plasmid Contributions to Colistin Resistance and Virulence in KPC-Producing Klebsiella Pneumoniae
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R21 AI128338
Start Year: 2016
End Year: 2018
Title: Evaluation of In Vitro Activity of Fosfomycin Alone or in Combination with Newly Introduced ß-Lactam Agents Against Carbapenem-Resistant Pseudomonas Aeruginosa and Enterobacteriaceae Clinical Isolates
Role: Principal Investigator
Funding Agency: Zavante Therapeutics, Inc.
Grant Number: RES
Start Year: 2016
End Year: 2017
Title: A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
Role: Principal Investigator
Funding Agency: Social and Scientific Systems, Inc./National Cancer Institute
Start Year: 2015
End Year: 2016
Title: A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza
Role: Principal Investigator
Funding Agency: Social and Scientific Systems, Inc./National Institute of Health
Start Year: 2015
End Year: 2015
Title: A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza
Role: Principal Investigator
Funding Agency: Social and Scientific Systems, Inc./National Institute of Allergy & Infectious Diseases
Start Year: 2015
End Year: 2015
Title: Candida Albicans Gene Expression During Intra-abdominal Infections
Role: Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R21 AI107290
Start Year: 2014
End Year: 2017
Title: Prospective Cohort Study of Cryptococcosis
Role: Principal Investigator
Funding Agency: Johns Hopkins University/National Institute of Allergy & Infectious Diseases
Grant Number: U01 AI109657
Start Year: 2014
End Year: 2016
Title: Antibacterial Resistance Leadership Group: CREST
Role: Principal Investigator
Funding Agency: Duke University/National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI04681
Start Year: 2014
End Year: 2015
Title: Clinical Laboratory Diagnostics for Invasive Aspergillosis
Role: Principal Investigator
Funding Agency: University of Florida/National Institute of Health
Start Year: 2010
End Year: 2015
Title: Imaging and PK-PD of Micafungin at Site of Candida Glabrata Infection In Vivo
Role: Co-Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R21 AI121555
Start Year: 2015
End Year: 2017
Title: Evolution of KPC-K. Pneumoniae that Persist in Patients on Prolonged Antibiotics
Role: Co-Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R21 AI111037
Start Year: 2014
End Year: 2016
Title: Marker Predicting Response to Therapy for KPC-producing Klebsiella Pneumoniae
Role: Co-Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R21 AI107302
Start Year: 2013
End Year: 2016